Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1949 1
1950 1
1968 1
1969 5
1970 1
1971 1
1972 3
1973 2
1974 4
1977 1
1979 1
1983 2
1984 2
1985 2
1986 3
1987 2
1988 5
1989 4
1990 5
1991 1
1992 2
1993 2
1994 2
1995 1
1996 1
1997 1
1999 2
2000 3
2001 6
2002 2
2003 6
2004 2
2005 3
2006 3
2007 8
2008 3
2009 6
2010 3
2011 6
2012 5
2013 3
2014 8
2015 6
2016 8
2017 5
2018 9
2019 9
2020 9
2021 6
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

168 results
Results by year
Filters applied: . Clear all
Page 1
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Fraser G, Cramer P, Demirkan F, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Pavlovsky MA, Karlsson C, Hallek M, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Chanan-Khan A. Fraser G, et al. Among authors: howes a. Leukemia. 2019 Apr;33(4):969-980. doi: 10.1038/s41375-018-0276-9. Epub 2018 Oct 12. Leukemia. 2019. PMID: 30315239 Free PMC article. Clinical Trial.
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, Pristupa A, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Pylypenko H, Loscertales J, Avigdor A, Rule S, Villa D, Samoilova O, Panagiotidis P, Goy A, Mato A, Pavlovsky MA, Karlsson C, Mahler M, Salman M, Sun S, Phelps C, Balasubramanian S, Howes A, Hallek M; HELIOS investigators. Chanan-Khan A, et al. Among authors: howes a. Lancet Oncol. 2016 Feb;17(2):200-211. doi: 10.1016/S1470-2045(15)00465-9. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26655421 Clinical Trial.
The regulation of IL-10 expression.
Gabryšová L, Howes A, Saraiva M, O'Garra A. Gabryšová L, et al. Among authors: howes a. Curr Top Microbiol Immunol. 2014;380:157-90. doi: 10.1007/978-3-662-43492-5_8. Curr Top Microbiol Immunol. 2014. PMID: 25004818 Free article. Review.
Time-dose relationships in radiotherapy.
Fowler JF, Thomlinson RH, Howes AE. Fowler JF, et al. Among authors: howes ae. Eur J Cancer. 1970 Jun;6(3):207-21. doi: 10.1016/0014-2964(70)90024-1. Eur J Cancer. 1970. PMID: 4920612 Review. No abstract available.
Optical Limiting Based on Huygens' Metasurfaces.
Howes A, Zhu Z, Curie D, Avila JR, Wheeler VD, Haglund RF, Valentine JG. Howes A, et al. Nano Lett. 2020 Jun 10;20(6):4638-4644. doi: 10.1021/acs.nanolett.0c01574. Epub 2020 May 22. Nano Lett. 2020. PMID: 32421337
Hematologic Abnormality in a Young Soldier.
Howes AB. Howes AB. Am Fam Physician. 2019 Aug 1;100(3):176-178. Am Fam Physician. 2019. PMID: 31361098 Free article. No abstract available.
A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
Liddle J, Beneton V, Benson M, Bingham R, Bouillot A, Boullay AB, Brook E, Cryan J, Denis A, Edgar E, Ferrie A, Fouchet MH, Grillot D, Holmes DS, Howes A, Krysa G, Laroze A, Lennon M, McClure F, Moquette A, Nicodeme E, Santiago B, Santos L, Smith KJ, Thorpe JH, Thripp G, Trottet L, Walker AL, Ward SA, Wang Y, Wilson S, Pearce AC, Hovnanian A. Liddle J, et al. Among authors: howes a. J Invest Dermatol. 2021 Sep;141(9):2272-2279. doi: 10.1016/j.jid.2021.01.029. Epub 2021 Mar 18. J Invest Dermatol. 2021. PMID: 33744298
168 results